Franz-Werner Haas, formerly chief executive of CureVac SE, has joined the Swiss vaccine developer LimmaTech Biologics AG which is developing vaccines to prevent bacterial infections. In addition to leading CureVac as CEO, Dr Haas was also the company’s chief corporate officer and chief operating officer. Prior to this, he was head of operations and compliance at SYGNIS Pharma AG where he was responsible for M&A and capital market transactions. He holds a Doctor of Laws degree and studied at the University of Saarbrücken in Germany, Catholic University of Leuven in Belgium, and the University of Edinburgh in the UK.
LimmaTech Biologics announced the appointment on 20 July 2023.
Copyright 2023 Evernow Publishing Ltd